Subcutaneous Mirikizumab Maintenance Treatment Over 40 Weeks Leads to Incremental Improvements in Rates of Clinical Remission and Endoscopic Response: Results from the Phase 3 VIV…

P Bossuyt, D Laharie, S Brand, D Bettenworth, J O Lindsey, S Maier, M Protic, E Hon, H Carlier, H Zang, G Yu, W Reinisch · Zeitschrift für Gastroenterologie · 2026 · Heft 05 · S. e140-e141